Latest Headlines

Latest Headlines

Clearside's novel eye drug delivery tech shows promise in latest clinical trial

Eyecare company Clearside Biomedical announced that patients treated with its injectable eye disease candidate demonstrated improved vision, as it tries to become the first to commercialize suprachoroidal delivery.

Nicox adds to eye-drug pipeline with $120M buyout deal for Aciex

In a deal designed to beef up its pipeline of ophthalmology drugs, France's Nicox has snapped up Boston-based Aciex for $65 million in newly issued shares and up to $55 million in contingent value rights. Those CVRs are structured to pay off Aciex's investors in large part based on the success of Aciex's drug AC-170, which has been in Phase III studies for allergic conjunctivitis.

Merck sells some eye-drug assets to Japan's Santen Pharma for $600M

The dealmaking continues in the red-hot market for eye care products with news today that Merck is offloading some of its ophthalmology products to Japan-based Santen Pharmaceutical.

Direct injection of drugs to back of eye shows potential

Clearside Biomedical presented human and animal study data showing the benefits of directly injecting medication into the eye's posterior suprachoroidal space at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL.

Novel glaucoma drug delivery platform described at ARVO conference

Startup Envisia Therapeutics is presenting the results of its ophthalmology research and technology allowing intracameral drug delivery at the Association for Research in Vision and Ophthalmology 2014 annual meeting in Orlando, FL. 

Acucela spots a $162M Japanese IPO to get its eye drug into focus

Seattle biotech Acucela is on track to test whether the stateside IPO boom has legs overseas, pricing a public offering in Japan for $162.3 million.

Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts

Regeneron Pharmaceuticals is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years.

Sanofi lets go of rights to Regeneron's antibodies in ophthalmology

Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi for full rights to the pair of antibody programs for use against eye diseases.

DEAL SPREE: Shire adds PhIII eye drug in $160M SARcode buyout

Fast-changing Shire is on a deal spree. This morning the biotech announced it is buying Brisbane, CA-based SARcode Bioscience for $160 million upfront and an unspecified slate of milestones. The buyout lands another ophthalmology asset for Shire, which closed on Sweden's Premacure just days ago.

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

Building on a $420 million deal it already has in place with Switzerland's Molecular Partners, Allergan has come back to the bargaining table to deepen its pipeline for ophthalmic drugs. Allergan paid $62.5 million upfront and promised up to $1.4 billion dollars in milestones in the ambitious deal, which covers a pair of R&D pacts.